Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854273 | 0.82 | HDAC6 (0.35) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL18290052 | 0.81 | MAPK1 (0.34) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL14976012 | 0.79 | CA14 (0.37) | CA14HDAC6APLNRHDAC1HDAC2 | |
| SCHEMBL1760208 | 0.77 | HDAC6 (0.35) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL29746689 | 0.76 | CA14 (0.40) | CA14HDAC6APLNRHDAC1HDAC2 | |
| SCHEMBL12778070 | 0.75 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL1025291 | 0.75 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL20866073 | 0.74 | CA14 (0.31) | CA14HDAC6APLNRHDAC1HDAC2 | |
| SCHEMBL2713441 | 0.73 | HDAC6 (0.35) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL31361087 | 0.73 | CA14 (0.44) | CA14HDAC6APLNRHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-115838375-A | Pyrimido-dihydro-pyrazolone derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3572413-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-2473510-B1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2473510-B1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8673933-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673933-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673933-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| US-8202881-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202881-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202881-B2 | JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | JAK2, JAK1, JAK3 | CA14 4400/4885HDAC6 852/4885APLNR 3036/4885 |
| US-20130225551-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | JAK2, JAK1, JAK3 | CA14 4400/4885HDAC6 852/4885APLNR 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.